SC-2001

SC-2001 is a small-molecule obatoclax analog and STAT3 inhibitor developed by researchers at National Taiwan University Hospital, National Yang-Ming University, Taipei Veterans General Hospital, and the Industrial Technology Research Institute. It acts by enhancing the expression and activity of the protein tyrosine phosphatase SHP-1 (Src homology region 2 domain-containing phosphatase-1) via the transcription factor RFX-1. This upregulation of SHP-1 leads to the dephosphorylation and inactivation of STAT3 (specifically at Tyr 705), subsequently downregulating STAT3-regulated proteins such as Mcl-1, survivin, and cyclin D1. Additionally, SC-2001 directly inhibits the protein-protein interactions between Mcl-1 and Bak. It has demonstrated preclinical efficacy in inducing apoptosis and inhibiting tumor growth in breast cancer and hepatocellular carcinoma (HCC), including overcoming sorafenib resistance in HCC models.

Other names

(Z)-2-((3-methoxy-2H-pyrrol-2-ylidene)methyl)-1H-pyrroleSC2001SC-2001SC 2001obatoclax analog SC-2001